nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluoxetine—SIGMAR1—amyotrophic lateral sclerosis	0.648	1	CbGaD
Fluoxetine—CYP1A2—Riluzole—amyotrophic lateral sclerosis	0.101	1	CbGbCtD
Fluoxetine—HTR2A—phrenic nerve—amyotrophic lateral sclerosis	0.00623	0.194	CbGeAlD
Fluoxetine—CNS depression NOS—Riluzole—amyotrophic lateral sclerosis	0.00172	0.00796	CcSEcCtD
Fluoxetine—Fungal skin infection—Riluzole—amyotrophic lateral sclerosis	0.00169	0.00782	CcSEcCtD
Fluoxetine—Paranoid reaction—Riluzole—amyotrophic lateral sclerosis	0.00166	0.00768	CcSEcCtD
Fluoxetine—Furunculosis—Riluzole—amyotrophic lateral sclerosis	0.00166	0.00768	CcSEcCtD
Fluoxetine—Personality disorder—Riluzole—amyotrophic lateral sclerosis	0.00163	0.00755	CcSEcCtD
Fluoxetine—HTR2A—cranial nerve—amyotrophic lateral sclerosis	0.00162	0.0505	CbGeAlD
Fluoxetine—HTR2A—pons—amyotrophic lateral sclerosis	0.0016	0.0499	CbGeAlD
Fluoxetine—Paraesthesia oral—Riluzole—amyotrophic lateral sclerosis	0.0015	0.00696	CcSEcCtD
Fluoxetine—Thrombocytopenic purpura—Riluzole—amyotrophic lateral sclerosis	0.0015	0.00696	CcSEcCtD
Fluoxetine—Cerebral ischaemia—Riluzole—amyotrophic lateral sclerosis	0.00146	0.00676	CcSEcCtD
Fluoxetine—Priapism—Riluzole—amyotrophic lateral sclerosis	0.00146	0.00676	CcSEcCtD
Fluoxetine—Tongue discolouration—Riluzole—amyotrophic lateral sclerosis	0.00146	0.00676	CcSEcCtD
Fluoxetine—Peripheral vascular disorder—Riluzole—amyotrophic lateral sclerosis	0.00144	0.00666	CcSEcCtD
Fluoxetine—Furuncle—Riluzole—amyotrophic lateral sclerosis	0.00144	0.00666	CcSEcCtD
Fluoxetine—Pneumothorax—Riluzole—amyotrophic lateral sclerosis	0.00142	0.00656	CcSEcCtD
Fluoxetine—Bundle branch block—Riluzole—amyotrophic lateral sclerosis	0.0014	0.00647	CcSEcCtD
Fluoxetine—Faecal incontinence—Riluzole—amyotrophic lateral sclerosis	0.0014	0.00647	CcSEcCtD
Fluoxetine—SLC6A2—nerve—amyotrophic lateral sclerosis	0.00138	0.0431	CbGeAlD
Fluoxetine—HTR2A—hindlimb—amyotrophic lateral sclerosis	0.00137	0.0426	CbGeAlD
Fluoxetine—Renal pain—Riluzole—amyotrophic lateral sclerosis	0.00134	0.00621	CcSEcCtD
Fluoxetine—Hostility—Riluzole—amyotrophic lateral sclerosis	0.00127	0.0059	CcSEcCtD
Fluoxetine—Hypothermia—Riluzole—amyotrophic lateral sclerosis	0.00126	0.00583	CcSEcCtD
Fluoxetine—Osteoporosis—Riluzole—amyotrophic lateral sclerosis	0.00126	0.00583	CcSEcCtD
Fluoxetine—Body temperature decreased—Riluzole—amyotrophic lateral sclerosis	0.00126	0.00583	CcSEcCtD
Fluoxetine—Suicide attempt—Riluzole—amyotrophic lateral sclerosis	0.00124	0.00575	CcSEcCtD
Fluoxetine—Gingival bleeding—Riluzole—amyotrophic lateral sclerosis	0.00124	0.00575	CcSEcCtD
Fluoxetine—Micturition urgency—Riluzole—amyotrophic lateral sclerosis	0.00124	0.00575	CcSEcCtD
Fluoxetine—Cholecystitis—Riluzole—amyotrophic lateral sclerosis	0.00123	0.00569	CcSEcCtD
Fluoxetine—Gastric ulcer—Riluzole—amyotrophic lateral sclerosis	0.00121	0.00562	CcSEcCtD
Fluoxetine—Completed suicide—Riluzole—amyotrophic lateral sclerosis	0.0012	0.00555	CcSEcCtD
Fluoxetine—Generalised oedema—Riluzole—amyotrophic lateral sclerosis	0.00118	0.00549	CcSEcCtD
Fluoxetine—SLC6A4—hindbrain—amyotrophic lateral sclerosis	0.00118	0.0366	CbGeAlD
Fluoxetine—HTR2A—appendage—amyotrophic lateral sclerosis	0.00117	0.0365	CbGeAlD
Fluoxetine—Enlargement abdomen—Riluzole—amyotrophic lateral sclerosis	0.00117	0.00543	CcSEcCtD
Fluoxetine—Myoclonus—Riluzole—amyotrophic lateral sclerosis	0.00117	0.00543	CcSEcCtD
Fluoxetine—Libido increased—Riluzole—amyotrophic lateral sclerosis	0.00116	0.00537	CcSEcCtD
Fluoxetine—Blepharitis—Riluzole—amyotrophic lateral sclerosis	0.00115	0.00531	CcSEcCtD
Fluoxetine—Psoriasis—Riluzole—amyotrophic lateral sclerosis	0.00112	0.0052	CcSEcCtD
Fluoxetine—Myasthenia—Riluzole—amyotrophic lateral sclerosis	0.00112	0.0052	CcSEcCtD
Fluoxetine—Respiratory distress—Riluzole—amyotrophic lateral sclerosis	0.00111	0.00514	CcSEcCtD
Fluoxetine—Hypoxia—Riluzole—amyotrophic lateral sclerosis	0.00111	0.00514	CcSEcCtD
Fluoxetine—Calculus of kidney—Riluzole—amyotrophic lateral sclerosis	0.00108	0.00498	CcSEcCtD
Fluoxetine—HTR2A—peripheral nervous system—amyotrophic lateral sclerosis	0.00107	0.0332	CbGeAlD
Fluoxetine—Paranoia—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00479	CcSEcCtD
Fluoxetine—Seborrhoeic dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00479	CcSEcCtD
Fluoxetine—Intestinal obstruction—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00479	CcSEcCtD
Fluoxetine—Hyperventilation—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00475	CcSEcCtD
Fluoxetine—Blood creatine phosphokinase increased—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00475	CcSEcCtD
Fluoxetine—Haematemesis—Riluzole—amyotrophic lateral sclerosis	0.00101	0.0047	CcSEcCtD
Fluoxetine—Depersonalisation—Riluzole—amyotrophic lateral sclerosis	0.001	0.00466	CcSEcCtD
Fluoxetine—Delusion—Riluzole—amyotrophic lateral sclerosis	0.000995	0.00461	CcSEcCtD
Fluoxetine—Thrombosis—Riluzole—amyotrophic lateral sclerosis	0.000995	0.00461	CcSEcCtD
Fluoxetine—Apathy—Riluzole—amyotrophic lateral sclerosis	0.000986	0.00457	CcSEcCtD
Fluoxetine—Metrorrhagia—Riluzole—amyotrophic lateral sclerosis	0.000986	0.00457	CcSEcCtD
Fluoxetine—Flat affect—Riluzole—amyotrophic lateral sclerosis	0.000977	0.00453	CcSEcCtD
Fluoxetine—Mania—Riluzole—amyotrophic lateral sclerosis	0.000969	0.00449	CcSEcCtD
Fluoxetine—Haemoptysis—Riluzole—amyotrophic lateral sclerosis	0.000952	0.00441	CcSEcCtD
Fluoxetine—Neuritis—Riluzole—amyotrophic lateral sclerosis	0.000944	0.00437	CcSEcCtD
Fluoxetine—Stupor—Riluzole—amyotrophic lateral sclerosis	0.000944	0.00437	CcSEcCtD
Fluoxetine—Glaucoma—Riluzole—amyotrophic lateral sclerosis	0.000936	0.00434	CcSEcCtD
Fluoxetine—Extrapyramidal disorder—Riluzole—amyotrophic lateral sclerosis	0.000936	0.00434	CcSEcCtD
Fluoxetine—Ventricular fibrillation—Riluzole—amyotrophic lateral sclerosis	0.00092	0.00426	CcSEcCtD
Fluoxetine—Pleural effusion—Riluzole—amyotrophic lateral sclerosis	0.00092	0.00426	CcSEcCtD
Fluoxetine—Amblyopia—Riluzole—amyotrophic lateral sclerosis	0.000912	0.00423	CcSEcCtD
Fluoxetine—Skin ulcer—Riluzole—amyotrophic lateral sclerosis	0.000905	0.00419	CcSEcCtD
Fluoxetine—Nephrolithiasis—Riluzole—amyotrophic lateral sclerosis	0.000876	0.00406	CcSEcCtD
Fluoxetine—Glycosuria—Riluzole—amyotrophic lateral sclerosis	0.00087	0.00403	CcSEcCtD
Fluoxetine—Ageusia—Riluzole—amyotrophic lateral sclerosis	0.00087	0.00403	CcSEcCtD
Fluoxetine—Petechiae—Riluzole—amyotrophic lateral sclerosis	0.000856	0.00397	CcSEcCtD
Fluoxetine—Liver injury—Riluzole—amyotrophic lateral sclerosis	0.000837	0.00388	CcSEcCtD
Fluoxetine—Apnoea—Riluzole—amyotrophic lateral sclerosis	0.000831	0.00385	CcSEcCtD
Fluoxetine—HTR2A—nerve—amyotrophic lateral sclerosis	0.000831	0.0259	CbGeAlD
Fluoxetine—Delirium—Riluzole—amyotrophic lateral sclerosis	0.000819	0.0038	CcSEcCtD
Fluoxetine—Breast pain—Riluzole—amyotrophic lateral sclerosis	0.000808	0.00374	CcSEcCtD
Fluoxetine—Amenorrhoea—Riluzole—amyotrophic lateral sclerosis	0.000802	0.00372	CcSEcCtD
Fluoxetine—Accidental injury—Riluzole—amyotrophic lateral sclerosis	0.000796	0.00369	CcSEcCtD
Fluoxetine—Musculoskeletal stiffness—Riluzole—amyotrophic lateral sclerosis	0.000785	0.00364	CcSEcCtD
Fluoxetine—Ventricular extrasystoles—Riluzole—amyotrophic lateral sclerosis	0.00078	0.00362	CcSEcCtD
Fluoxetine—Arthropathy—Riluzole—amyotrophic lateral sclerosis	0.000775	0.00359	CcSEcCtD
Fluoxetine—Thinking abnormal—Riluzole—amyotrophic lateral sclerosis	0.00077	0.00357	CcSEcCtD
Fluoxetine—Cough increased—Riluzole—amyotrophic lateral sclerosis	0.00077	0.00357	CcSEcCtD
Fluoxetine—Glossitis—Riluzole—amyotrophic lateral sclerosis	0.000765	0.00354	CcSEcCtD
Fluoxetine—Nocturia—Riluzole—amyotrophic lateral sclerosis	0.00076	0.00352	CcSEcCtD
Fluoxetine—Gout—Riluzole—amyotrophic lateral sclerosis	0.000755	0.0035	CcSEcCtD
Fluoxetine—Leukocytosis—Riluzole—amyotrophic lateral sclerosis	0.00075	0.00347	CcSEcCtD
Fluoxetine—Hypercholesterolaemia—Riluzole—amyotrophic lateral sclerosis	0.000745	0.00345	CcSEcCtD
Fluoxetine—Dysarthria—Riluzole—amyotrophic lateral sclerosis	0.000745	0.00345	CcSEcCtD
Fluoxetine—Cataract—Riluzole—amyotrophic lateral sclerosis	0.00074	0.00343	CcSEcCtD
Fluoxetine—Gait disturbance—Riluzole—amyotrophic lateral sclerosis	0.000722	0.00335	CcSEcCtD
Fluoxetine—Coordination abnormal—Riluzole—amyotrophic lateral sclerosis	0.000717	0.00333	CcSEcCtD
Fluoxetine—Respiratory failure—Riluzole—amyotrophic lateral sclerosis	0.000717	0.00333	CcSEcCtD
Fluoxetine—Neck pain—Riluzole—amyotrophic lateral sclerosis	0.000713	0.00331	CcSEcCtD
Fluoxetine—HTR2C—brainstem—amyotrophic lateral sclerosis	0.000711	0.0222	CbGeAlD
Fluoxetine—Pulmonary embolism—Riluzole—amyotrophic lateral sclerosis	0.000705	0.00327	CcSEcCtD
Fluoxetine—Phosphatase alkaline increased—Riluzole—amyotrophic lateral sclerosis	0.000705	0.00327	CcSEcCtD
Fluoxetine—Hiccups—Riluzole—amyotrophic lateral sclerosis	0.000705	0.00327	CcSEcCtD
Fluoxetine—Hepatocellular injury—Riluzole—amyotrophic lateral sclerosis	0.000705	0.00327	CcSEcCtD
Fluoxetine—Ventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.000705	0.00327	CcSEcCtD
Fluoxetine—Abnormal dreams—Riluzole—amyotrophic lateral sclerosis	0.000696	0.00323	CcSEcCtD
Fluoxetine—Dermatitis contact—Riluzole—amyotrophic lateral sclerosis	0.000696	0.00323	CcSEcCtD
Fluoxetine—Melaena—Riluzole—amyotrophic lateral sclerosis	0.000688	0.00319	CcSEcCtD
Fluoxetine—Depressed level of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00068	0.00315	CcSEcCtD
Fluoxetine—Urinary incontinence—Riluzole—amyotrophic lateral sclerosis	0.00068	0.00315	CcSEcCtD
Fluoxetine—SLC6A4—brainstem—amyotrophic lateral sclerosis	0.000674	0.021	CbGeAlD
Fluoxetine—Candida infection—Riluzole—amyotrophic lateral sclerosis	0.000673	0.00312	CcSEcCtD
Fluoxetine—Fluid retention—Riluzole—amyotrophic lateral sclerosis	0.000669	0.0031	CcSEcCtD
Fluoxetine—Photophobia—Riluzole—amyotrophic lateral sclerosis	0.000661	0.00307	CcSEcCtD
Fluoxetine—Aplastic anaemia—Riluzole—amyotrophic lateral sclerosis	0.000661	0.00307	CcSEcCtD
Fluoxetine—Cramps of lower extremities—Riluzole—amyotrophic lateral sclerosis	0.000647	0.003	CcSEcCtD
Fluoxetine—Coma—Riluzole—amyotrophic lateral sclerosis	0.000644	0.00298	CcSEcCtD
Fluoxetine—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.000637	0.00295	CcSEcCtD
Fluoxetine—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.000637	0.00295	CcSEcCtD
Fluoxetine—Pulmonary oedema—Riluzole—amyotrophic lateral sclerosis	0.000627	0.00291	CcSEcCtD
Fluoxetine—HTR2A—hindbrain—amyotrophic lateral sclerosis	0.000623	0.0194	CbGeAlD
Fluoxetine—Hypertonia—Riluzole—amyotrophic lateral sclerosis	0.000618	0.00286	CcSEcCtD
Fluoxetine—Mental disability—Riluzole—amyotrophic lateral sclerosis	0.000611	0.00283	CcSEcCtD
Fluoxetine—Euphoric mood—Riluzole—amyotrophic lateral sclerosis	0.000605	0.00281	CcSEcCtD
Fluoxetine—Ear pain—Riluzole—amyotrophic lateral sclerosis	0.000599	0.00278	CcSEcCtD
Fluoxetine—Lymphadenopathy—Riluzole—amyotrophic lateral sclerosis	0.000599	0.00278	CcSEcCtD
Fluoxetine—Phlebitis—Riluzole—amyotrophic lateral sclerosis	0.000594	0.00275	CcSEcCtD
Fluoxetine—SLC6A2—brainstem—amyotrophic lateral sclerosis	0.000594	0.0185	CbGeAlD
Fluoxetine—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.000588	0.00273	CcSEcCtD
Fluoxetine—Blood alkaline phosphatase increased—Riluzole—amyotrophic lateral sclerosis	0.000588	0.00273	CcSEcCtD
Fluoxetine—Vascular purpura—Riluzole—amyotrophic lateral sclerosis	0.000572	0.00265	CcSEcCtD
Fluoxetine—Deafness—Riluzole—amyotrophic lateral sclerosis	0.000572	0.00265	CcSEcCtD
Fluoxetine—Eczema—Riluzole—amyotrophic lateral sclerosis	0.000569	0.00264	CcSEcCtD
Fluoxetine—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.000567	0.0177	CbGeAlD
Fluoxetine—Cardiac failure congestive—Riluzole—amyotrophic lateral sclerosis	0.000564	0.00261	CcSEcCtD
Fluoxetine—Injury—Riluzole—amyotrophic lateral sclerosis	0.000556	0.00258	CcSEcCtD
Fluoxetine—Libido decreased—Riluzole—amyotrophic lateral sclerosis	0.000552	0.00256	CcSEcCtD
Fluoxetine—Amnesia—Riluzole—amyotrophic lateral sclerosis	0.000544	0.00252	CcSEcCtD
Fluoxetine—Increased appetite—Riluzole—amyotrophic lateral sclerosis	0.000544	0.00252	CcSEcCtD
Fluoxetine—Dermatitis exfoliative—Riluzole—amyotrophic lateral sclerosis	0.000542	0.00251	CcSEcCtD
Fluoxetine—Atrial fibrillation—Riluzole—amyotrophic lateral sclerosis	0.00054	0.0025	CcSEcCtD
Fluoxetine—Thirst—Riluzole—amyotrophic lateral sclerosis	0.000537	0.00249	CcSEcCtD
Fluoxetine—Purpura—Riluzole—amyotrophic lateral sclerosis	0.000531	0.00246	CcSEcCtD
Fluoxetine—Anaphylactoid reaction—Riluzole—amyotrophic lateral sclerosis	0.000528	0.00245	CcSEcCtD
Fluoxetine—Arthritis—Riluzole—amyotrophic lateral sclerosis	0.000526	0.00244	CcSEcCtD
Fluoxetine—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.000513	0.00238	CcSEcCtD
Fluoxetine—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.000511	0.00237	CcSEcCtD
Fluoxetine—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.000511	0.00237	CcSEcCtD
Fluoxetine—Diplopia—Riluzole—amyotrophic lateral sclerosis	0.000511	0.00237	CcSEcCtD
Fluoxetine—Disturbance in sexual arousal—Riluzole—amyotrophic lateral sclerosis	0.000507	0.00235	CcSEcCtD
Fluoxetine—Affect lability—Riluzole—amyotrophic lateral sclerosis	0.000503	0.00233	CcSEcCtD
Fluoxetine—Migraine—Riluzole—amyotrophic lateral sclerosis	0.000503	0.00233	CcSEcCtD
Fluoxetine—Psychotic disorder—Riluzole—amyotrophic lateral sclerosis	0.000499	0.00232	CcSEcCtD
Fluoxetine—HTR2C—medulla oblongata—amyotrophic lateral sclerosis	0.000496	0.0154	CbGeAlD
Fluoxetine—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.000494	0.00229	CcSEcCtD
Fluoxetine—ORM1—spinal cord—amyotrophic lateral sclerosis	0.000492	0.0153	CbGeAlD
Fluoxetine—Cardiac arrest—Riluzole—amyotrophic lateral sclerosis	0.000486	0.00225	CcSEcCtD
Fluoxetine—Urinary retention—Riluzole—amyotrophic lateral sclerosis	0.000486	0.00225	CcSEcCtD
Fluoxetine—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.000484	0.00225	CcSEcCtD
Fluoxetine—Ataxia—Riluzole—amyotrophic lateral sclerosis	0.000481	0.00223	CcSEcCtD
Fluoxetine—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.000476	0.0022	CcSEcCtD
Fluoxetine—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.000472	0.00219	CcSEcCtD
Fluoxetine—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.000467	0.00217	CcSEcCtD
Fluoxetine—SIGMAR1—medulla oblongata—amyotrophic lateral sclerosis	0.000467	0.0145	CbGeAlD
Fluoxetine—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.000465	0.00216	CcSEcCtD
Fluoxetine—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.000462	0.00214	CcSEcCtD
Fluoxetine—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.000453	0.0021	CcSEcCtD
Fluoxetine—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.000451	0.00209	CcSEcCtD
Fluoxetine—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.000451	0.00209	CcSEcCtD
Fluoxetine—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.000445	0.00206	CcSEcCtD
Fluoxetine—HTR2C—spinal cord—amyotrophic lateral sclerosis	0.000442	0.0138	CbGeAlD
Fluoxetine—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.000442	0.00205	CcSEcCtD
Fluoxetine—Asthma—Riluzole—amyotrophic lateral sclerosis	0.000442	0.00205	CcSEcCtD
Fluoxetine—Influenza—Riluzole—amyotrophic lateral sclerosis	0.000442	0.00205	CcSEcCtD
Fluoxetine—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.000433	0.00201	CcSEcCtD
Fluoxetine—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.000431	0.002	CcSEcCtD
Fluoxetine—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.000425	0.00197	CcSEcCtD
Fluoxetine—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.00042	0.00195	CcSEcCtD
Fluoxetine—SLC6A4—spinal cord—amyotrophic lateral sclerosis	0.000419	0.0131	CbGeAlD
Fluoxetine—SIGMAR1—spinal cord—amyotrophic lateral sclerosis	0.000416	0.013	CbGeAlD
Fluoxetine—ORM1—nervous system—amyotrophic lateral sclerosis	0.000415	0.0129	CbGeAlD
Fluoxetine—SLC6A2—medulla oblongata—amyotrophic lateral sclerosis	0.000414	0.0129	CbGeAlD
Fluoxetine—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.000413	0.00192	CcSEcCtD
Fluoxetine—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.000408	0.00189	CcSEcCtD
Fluoxetine—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.000407	0.00189	CcSEcCtD
Fluoxetine—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.000403	0.00187	CcSEcCtD
Fluoxetine—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.000402	0.00186	CcSEcCtD
Fluoxetine—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.0004	0.00185	CcSEcCtD
Fluoxetine—ORM1—central nervous system—amyotrophic lateral sclerosis	0.000399	0.0124	CbGeAlD
Fluoxetine—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.000396	0.00184	CcSEcCtD
Fluoxetine—Depression—Riluzole—amyotrophic lateral sclerosis	0.000393	0.00182	CcSEcCtD
Fluoxetine—HTR2A—embryo—amyotrophic lateral sclerosis	0.000389	0.0121	CbGeAlD
Fluoxetine—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.000389	0.0018	CcSEcCtD
Fluoxetine—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.000386	0.00179	CcSEcCtD
Fluoxetine—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.000386	0.00179	CcSEcCtD
Fluoxetine—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.000384	0.00178	CcSEcCtD
Fluoxetine—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.000384	0.00178	CcSEcCtD
Fluoxetine—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.000383	0.00178	CcSEcCtD
Fluoxetine—Sweating—Riluzole—amyotrophic lateral sclerosis	0.000378	0.00175	CcSEcCtD
Fluoxetine—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.000376	0.00174	CcSEcCtD
Fluoxetine—HTR2C—nervous system—amyotrophic lateral sclerosis	0.000373	0.0116	CbGeAlD
Fluoxetine—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.000372	0.00172	CcSEcCtD
Fluoxetine—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.00037	0.00171	CcSEcCtD
Fluoxetine—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.00036	0.00167	CcSEcCtD
Fluoxetine—HTR2C—central nervous system—amyotrophic lateral sclerosis	0.000359	0.0112	CbGeAlD
Fluoxetine—HTR2A—brainstem—amyotrophic lateral sclerosis	0.000357	0.0111	CbGeAlD
Fluoxetine—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.000356	0.00165	CcSEcCtD
Fluoxetine—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.000355	0.00164	CcSEcCtD
Fluoxetine—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.000354	0.00164	CcSEcCtD
Fluoxetine—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.000354	0.00164	CcSEcCtD
Fluoxetine—SLC6A4—nervous system—amyotrophic lateral sclerosis	0.000353	0.011	CbGeAlD
Fluoxetine—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.000352	0.00163	CcSEcCtD
Fluoxetine—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.000352	0.00163	CcSEcCtD
Fluoxetine—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.000351	0.00163	CcSEcCtD
Fluoxetine—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.000349	0.00162	CcSEcCtD
Fluoxetine—SLC6A4—central nervous system—amyotrophic lateral sclerosis	0.00034	0.0106	CbGeAlD
Fluoxetine—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.000335	0.00155	CcSEcCtD
Fluoxetine—SIGMAR1—cerebellum—amyotrophic lateral sclerosis	0.00033	0.0103	CbGeAlD
Fluoxetine—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.000325	0.0101	CbGeAlD
Fluoxetine—Chills—Riluzole—amyotrophic lateral sclerosis	0.000317	0.00147	CcSEcCtD
Fluoxetine—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.000316	0.00146	CcSEcCtD
Fluoxetine—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.000313	0.00145	CcSEcCtD
Fluoxetine—SLC6A2—nervous system—amyotrophic lateral sclerosis	0.000311	0.00969	CbGeAlD
Fluoxetine—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00031	0.00144	CcSEcCtD
Fluoxetine—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.000308	0.00143	CcSEcCtD
Fluoxetine—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.000303	0.00141	CcSEcCtD
Fluoxetine—Tension—Riluzole—amyotrophic lateral sclerosis	0.000302	0.0014	CcSEcCtD
Fluoxetine—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.000302	0.0014	CcSEcCtD
Fluoxetine—SLC6A2—central nervous system—amyotrophic lateral sclerosis	0.000299	0.00933	CbGeAlD
Fluoxetine—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.000299	0.00139	CcSEcCtD
Fluoxetine—Back pain—Riluzole—amyotrophic lateral sclerosis	0.000298	0.00138	CcSEcCtD
Fluoxetine—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.000296	0.00137	CcSEcCtD
Fluoxetine—Tremor—Riluzole—amyotrophic lateral sclerosis	0.000289	0.00134	CcSEcCtD
Fluoxetine—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.000286	0.00132	CcSEcCtD
Fluoxetine—HTR2C—brain—amyotrophic lateral sclerosis	0.000285	0.00887	CbGeAlD
Fluoxetine—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.000285	0.00132	CcSEcCtD
Fluoxetine—Agitation—Riluzole—amyotrophic lateral sclerosis	0.000283	0.00131	CcSEcCtD
Fluoxetine—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.000281	0.0013	CcSEcCtD
Fluoxetine—ALB—brain—amyotrophic lateral sclerosis	0.000278	0.00866	CbGeAlD
Fluoxetine—Malaise—Riluzole—amyotrophic lateral sclerosis	0.000278	0.00129	CcSEcCtD
Fluoxetine—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.000277	0.00128	CcSEcCtD
Fluoxetine—Syncope—Riluzole—amyotrophic lateral sclerosis	0.000276	0.00128	CcSEcCtD
Fluoxetine—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.000276	0.00128	CcSEcCtD
Fluoxetine—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.000272	0.00126	CcSEcCtD
Fluoxetine—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.000271	0.00125	CcSEcCtD
Fluoxetine—SLC6A4—brain—amyotrophic lateral sclerosis	0.00027	0.00841	CbGeAlD
Fluoxetine—Cough—Riluzole—amyotrophic lateral sclerosis	0.000269	0.00125	CcSEcCtD
Fluoxetine—SIGMAR1—brain—amyotrophic lateral sclerosis	0.000268	0.00835	CbGeAlD
Fluoxetine—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.000267	0.00124	CcSEcCtD
Fluoxetine—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.000266	0.00123	CcSEcCtD
Fluoxetine—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.000262	0.00122	CcSEcCtD
Fluoxetine—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.000262	0.00122	CcSEcCtD
Fluoxetine—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.000262	0.00122	CcSEcCtD
Fluoxetine—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.000261	0.00121	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00026	0.00121	CcSEcCtD
Fluoxetine—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.000259	0.0012	CcSEcCtD
Fluoxetine—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.000256	0.00119	CcSEcCtD
Fluoxetine—ABCB1—embryo—amyotrophic lateral sclerosis	0.000255	0.00795	CbGeAlD
Fluoxetine—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.000253	0.00117	CcSEcCtD
Fluoxetine—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.000251	0.00117	CcSEcCtD
Fluoxetine—Infection—Riluzole—amyotrophic lateral sclerosis	0.00025	0.00116	CcSEcCtD
Fluoxetine—HTR2A—medulla oblongata—amyotrophic lateral sclerosis	0.000249	0.00775	CbGeAlD
Fluoxetine—Shock—Riluzole—amyotrophic lateral sclerosis	0.000247	0.00115	CcSEcCtD
Fluoxetine—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.000246	0.00114	CcSEcCtD
Fluoxetine—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.000245	0.00114	CcSEcCtD
Fluoxetine—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.000244	0.00113	CcSEcCtD
Fluoxetine—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.000243	0.00113	CcSEcCtD
Fluoxetine—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00024	0.00111	CcSEcCtD
Fluoxetine—SLC6A2—brain—amyotrophic lateral sclerosis	0.000238	0.0074	CbGeAlD
Fluoxetine—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.000235	0.00109	CcSEcCtD
Fluoxetine—CYP2B6—nervous system—amyotrophic lateral sclerosis	0.000229	0.00714	CbGeAlD
Fluoxetine—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000229	0.00106	CcSEcCtD
Fluoxetine—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.000227	0.00105	CcSEcCtD
Fluoxetine—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.000226	0.00105	CcSEcCtD
Fluoxetine—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.000224	0.00104	CcSEcCtD
Fluoxetine—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.000223	0.00104	CcSEcCtD
Fluoxetine—HTR2A—spinal cord—amyotrophic lateral sclerosis	0.000222	0.00691	CbGeAlD
Fluoxetine—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.000221	0.00103	CcSEcCtD
Fluoxetine—CYP2B6—central nervous system—amyotrophic lateral sclerosis	0.000221	0.00687	CbGeAlD
Fluoxetine—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.000219	0.00101	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000217	0.00101	CcSEcCtD
Fluoxetine—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.000217	0.001	CcSEcCtD
Fluoxetine—Constipation—Riluzole—amyotrophic lateral sclerosis	0.000215	0.000996	CcSEcCtD
Fluoxetine—Pain—Riluzole—amyotrophic lateral sclerosis	0.000215	0.000996	CcSEcCtD
Fluoxetine—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.000207	0.00096	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.000206	0.000953	CcSEcCtD
Fluoxetine—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.0002	0.000926	CcSEcCtD
Fluoxetine—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.000199	0.000921	CcSEcCtD
Fluoxetine—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000199	0.000921	CcSEcCtD
Fluoxetine—HTR2A—nervous system—amyotrophic lateral sclerosis	0.000187	0.00582	CbGeAlD
Fluoxetine—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000185	0.000858	CcSEcCtD
Fluoxetine—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00018	0.000836	CcSEcCtD
Fluoxetine—HTR2A—central nervous system—amyotrophic lateral sclerosis	0.00018	0.00561	CbGeAlD
Fluoxetine—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000178	0.000824	CcSEcCtD
Fluoxetine—HTR2A—cerebellum—amyotrophic lateral sclerosis	0.000176	0.00548	CbGeAlD
Fluoxetine—CYP2B6—brain—amyotrophic lateral sclerosis	0.000175	0.00546	CbGeAlD
Fluoxetine—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.000173	0.00539	CbGeAlD
Fluoxetine—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000172	0.000797	CcSEcCtD
Fluoxetine—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.00017	0.0053	CbGeAlD
Fluoxetine—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000167	0.00519	CbGeAlD
Fluoxetine—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000166	0.00077	CcSEcCtD
Fluoxetine—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.000164	0.00511	CbGeAlD
Fluoxetine—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	0.000163	0.00508	CbGeAlD
Fluoxetine—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.00016	0.00499	CbGeAlD
Fluoxetine—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00016	0.000741	CcSEcCtD
Fluoxetine—Rash—Riluzole—amyotrophic lateral sclerosis	0.000158	0.000735	CcSEcCtD
Fluoxetine—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000158	0.000734	CcSEcCtD
Fluoxetine—Headache—Riluzole—amyotrophic lateral sclerosis	0.000157	0.00073	CcSEcCtD
Fluoxetine—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000149	0.000692	CcSEcCtD
Fluoxetine—ABCB1—spinal cord—amyotrophic lateral sclerosis	0.000145	0.00453	CbGeAlD
Fluoxetine—HTR2A—brain—amyotrophic lateral sclerosis	0.000143	0.00445	CbGeAlD
Fluoxetine—CYP2D6—brain—amyotrophic lateral sclerosis	0.00013	0.00405	CbGeAlD
Fluoxetine—ABCB1—nervous system—amyotrophic lateral sclerosis	0.000122	0.00382	CbGeAlD
Fluoxetine—ABCB1—central nervous system—amyotrophic lateral sclerosis	0.000118	0.00367	CbGeAlD
Fluoxetine—ABCB1—cerebellum—amyotrophic lateral sclerosis	0.000115	0.00359	CbGeAlD
Fluoxetine—ABCB1—brain—amyotrophic lateral sclerosis	9.36e-05	0.00292	CbGeAlD
Fluoxetine—CYP2B6—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	7.87e-06	0.00217	CbGpPWpGaD
Fluoxetine—CYP3A5—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	7.8e-06	0.00215	CbGpPWpGaD
Fluoxetine—ALB—Platelet degranulation—IGF1—amyotrophic lateral sclerosis	7.75e-06	0.00213	CbGpPWpGaD
Fluoxetine—CYP3A5—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	7.7e-06	0.00212	CbGpPWpGaD
Fluoxetine—CYP2C9—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	7.66e-06	0.00211	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	7.57e-06	0.00208	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	7.4e-06	0.00204	CbGpPWpGaD
Fluoxetine—ALB—Response to elevated platelet cytosolic Ca2+—IGF1—amyotrophic lateral sclerosis	7.38e-06	0.00203	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	7.3e-06	0.00201	CbGpPWpGaD
Fluoxetine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—amyotrophic lateral sclerosis	6.99e-06	0.00193	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	6.88e-06	0.00189	CbGpPWpGaD
Fluoxetine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	6.86e-06	0.00189	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—TUBA4A—amyotrophic lateral sclerosis	6.67e-06	0.00184	CbGpPWpGaD
Fluoxetine—CYP1A2—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	6.54e-06	0.0018	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	6.47e-06	0.00178	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	6.34e-06	0.00174	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—RAB5A—amyotrophic lateral sclerosis	6.2e-06	0.00171	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	6.18e-06	0.0017	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—VAPB—amyotrophic lateral sclerosis	6.12e-06	0.00168	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—TPK1—amyotrophic lateral sclerosis	6.12e-06	0.00168	CbGpPWpGaD
Fluoxetine—CYP2C19—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	6.03e-06	0.00166	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—PFN1—amyotrophic lateral sclerosis	6.01e-06	0.00165	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—VAPB—amyotrophic lateral sclerosis	5.98e-06	0.00165	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—TPK1—amyotrophic lateral sclerosis	5.98e-06	0.00165	CbGpPWpGaD
Fluoxetine—ALB—Selenium Micronutrient Network—PTGS2—amyotrophic lateral sclerosis	5.95e-06	0.00164	CbGpPWpGaD
Fluoxetine—CYP2C19—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	5.95e-06	0.00164	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	5.69e-06	0.00157	CbGpPWpGaD
Fluoxetine—ALB—Platelet activation, signaling and aggregation—SOD1—amyotrophic lateral sclerosis	5.63e-06	0.00155	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—VAPA—amyotrophic lateral sclerosis	5.6e-06	0.00154	CbGpPWpGaD
Fluoxetine—CYP2D6—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	5.55e-06	0.00153	CbGpPWpGaD
Fluoxetine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	5.51e-06	0.00152	CbGpPWpGaD
Fluoxetine—CYP2C9—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	5.5e-06	0.00151	CbGpPWpGaD
Fluoxetine—CYP2D6—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	5.47e-06	0.00151	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—VAPA—amyotrophic lateral sclerosis	5.47e-06	0.00151	CbGpPWpGaD
Fluoxetine—CYP2C9—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	5.43e-06	0.00149	CbGpPWpGaD
Fluoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	5.42e-06	0.00149	CbGpPWpGaD
Fluoxetine—ALB—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	5.37e-06	0.00148	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	5.35e-06	0.00147	CbGpPWpGaD
Fluoxetine—ABCB1—Allograft Rejection—CASP3—amyotrophic lateral sclerosis	5.28e-06	0.00145	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	5.21e-06	0.00144	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—SACM1L—amyotrophic lateral sclerosis	5.2e-06	0.00143	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	5.19e-06	0.00143	CbGpPWpGaD
Fluoxetine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—amyotrophic lateral sclerosis	5.17e-06	0.00142	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—VAPB—amyotrophic lateral sclerosis	5.15e-06	0.00142	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—TPK1—amyotrophic lateral sclerosis	5.15e-06	0.00142	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—SACM1L—amyotrophic lateral sclerosis	5.08e-06	0.0014	CbGpPWpGaD
Fluoxetine—ALB—Platelet degranulation—VEGFA—amyotrophic lateral sclerosis	5.06e-06	0.00139	CbGpPWpGaD
Fluoxetine—ALB—Platelet activation, signaling and aggregation—PLA2G4A—amyotrophic lateral sclerosis	5.05e-06	0.00139	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	4.98e-06	0.00137	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—FIG4—amyotrophic lateral sclerosis	4.89e-06	0.00135	CbGpPWpGaD
Fluoxetine—HTR2A—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	4.87e-06	0.00134	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	4.85e-06	0.00134	CbGpPWpGaD
Fluoxetine—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—amyotrophic lateral sclerosis	4.82e-06	0.00133	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	4.8e-06	0.00132	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—FIG4—amyotrophic lateral sclerosis	4.78e-06	0.00132	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—VAPA—amyotrophic lateral sclerosis	4.71e-06	0.0013	CbGpPWpGaD
Fluoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	4.71e-06	0.0013	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	4.7e-06	0.0013	CbGpPWpGaD
Fluoxetine—CYP1A2—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	4.7e-06	0.00129	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	4.64e-06	0.00128	CbGpPWpGaD
Fluoxetine—CYP1A2—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	4.64e-06	0.00128	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—VAPB—amyotrophic lateral sclerosis	4.62e-06	0.00127	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—TPK1—amyotrophic lateral sclerosis	4.62e-06	0.00127	CbGpPWpGaD
Fluoxetine—ALB—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	4.57e-06	0.00126	CbGpPWpGaD
Fluoxetine—ALB—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	4.57e-06	0.00126	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—VAPB—amyotrophic lateral sclerosis	4.51e-06	0.00124	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—TPK1—amyotrophic lateral sclerosis	4.51e-06	0.00124	CbGpPWpGaD
Fluoxetine—ABCB1—Allograft Rejection—VEGFA—amyotrophic lateral sclerosis	4.48e-06	0.00123	CbGpPWpGaD
Fluoxetine—ALB—Folate Metabolism—TP53—amyotrophic lateral sclerosis	4.46e-06	0.00123	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	4.43e-06	0.00122	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—DAO—amyotrophic lateral sclerosis	4.42e-06	0.00122	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—SACM1L—amyotrophic lateral sclerosis	4.38e-06	0.00121	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—DAO—amyotrophic lateral sclerosis	4.32e-06	0.00119	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	4.31e-06	0.00119	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—VAPB—amyotrophic lateral sclerosis	4.25e-06	0.00117	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—TPK1—amyotrophic lateral sclerosis	4.25e-06	0.00117	CbGpPWpGaD
Fluoxetine—SLC6A4—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	4.23e-06	0.00117	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—VAPA—amyotrophic lateral sclerosis	4.23e-06	0.00116	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	4.22e-06	0.00116	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—TPK1—amyotrophic lateral sclerosis	4.22e-06	0.00116	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—VAPB—amyotrophic lateral sclerosis	4.22e-06	0.00116	CbGpPWpGaD
Fluoxetine—HTR2A—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	4.13e-06	0.00114	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR ligand binding—C3—amyotrophic lateral sclerosis	4.13e-06	0.00114	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—VAPA—amyotrophic lateral sclerosis	4.13e-06	0.00114	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—FIG4—amyotrophic lateral sclerosis	4.12e-06	0.00113	CbGpPWpGaD
Fluoxetine—ALB—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	4.07e-06	0.00112	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	4e-06	0.0011	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	4e-06	0.0011	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.93e-06	0.00108	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	3.93e-06	0.00108	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—VAPA—amyotrophic lateral sclerosis	3.89e-06	0.00107	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—VAPA—amyotrophic lateral sclerosis	3.86e-06	0.00106	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.84e-06	0.00106	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	3.78e-06	0.00104	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—DAO—amyotrophic lateral sclerosis	3.72e-06	0.00103	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—FIG4—amyotrophic lateral sclerosis	3.7e-06	0.00102	CbGpPWpGaD
Fluoxetine—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	3.63e-06	0.000999	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.62e-06	0.000996	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—FIG4—amyotrophic lateral sclerosis	3.61e-06	0.000993	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—TPK1—amyotrophic lateral sclerosis	3.6e-06	0.000992	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—VAPB—amyotrophic lateral sclerosis	3.6e-06	0.000992	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR ligand binding—C3—amyotrophic lateral sclerosis	3.59e-06	0.000987	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.58e-06	0.000987	CbGpPWpGaD
Fluoxetine—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	3.58e-06	0.000985	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	3.57e-06	0.000982	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	3.56e-06	0.00098	CbGpPWpGaD
Fluoxetine—ALB—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	3.44e-06	0.000946	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—FIG4—amyotrophic lateral sclerosis	3.4e-06	0.000936	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	3.38e-06	0.000932	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—VCP—amyotrophic lateral sclerosis	3.37e-06	0.000929	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—FIG4—amyotrophic lateral sclerosis	3.37e-06	0.000928	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	3.36e-06	0.000925	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PLB1—amyotrophic lateral sclerosis	3.35e-06	0.000923	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—DAO—amyotrophic lateral sclerosis	3.34e-06	0.00092	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—VAPA—amyotrophic lateral sclerosis	3.29e-06	0.000907	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	3.29e-06	0.000905	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PLB1—amyotrophic lateral sclerosis	3.28e-06	0.000902	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	3.27e-06	0.000899	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—DAO—amyotrophic lateral sclerosis	3.26e-06	0.000898	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—GSR—amyotrophic lateral sclerosis	3.09e-06	0.000852	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	3.09e-06	0.000851	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	3.07e-06	0.000846	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.06e-06	0.000843	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—DAO—amyotrophic lateral sclerosis	3.05e-06	0.000839	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—GSR—amyotrophic lateral sclerosis	3.02e-06	0.000833	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—VCP—amyotrophic lateral sclerosis	2.93e-06	0.000806	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—SOD1—amyotrophic lateral sclerosis	2.9e-06	0.0008	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	2.9e-06	0.000799	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—FIG4—amyotrophic lateral sclerosis	2.88e-06	0.000793	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	2.87e-06	0.00079	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	2.84e-06	0.000781	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PLB1—amyotrophic lateral sclerosis	2.82e-06	0.000777	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	2.81e-06	0.000772	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	2.78e-06	0.000765	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	2.78e-06	0.000765	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	2.61e-06	0.000717	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—DAO—amyotrophic lateral sclerosis	2.6e-06	0.000717	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	2.6e-06	0.000717	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—GSR—amyotrophic lateral sclerosis	2.6e-06	0.000717	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	2.54e-06	0.0007	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—CHAT—amyotrophic lateral sclerosis	2.54e-06	0.0007	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PLB1—amyotrophic lateral sclerosis	2.53e-06	0.000697	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	2.52e-06	0.000694	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	2.49e-06	0.000686	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—CHAT—amyotrophic lateral sclerosis	2.48e-06	0.000684	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	2.47e-06	0.000681	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	2.4e-06	0.00066	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.37e-06	0.000653	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.36e-06	0.000651	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—GSR—amyotrophic lateral sclerosis	2.34e-06	0.000644	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	2.33e-06	0.000643	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	2.33e-06	0.000642	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PLB1—amyotrophic lateral sclerosis	2.31e-06	0.000636	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	2.28e-06	0.000628	CbGpPWpGaD
Fluoxetine—ALB—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	2.24e-06	0.000618	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	2.22e-06	0.000612	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	2.21e-06	0.000608	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	2.15e-06	0.000592	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—CHAT—amyotrophic lateral sclerosis	2.14e-06	0.000589	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GSR—amyotrophic lateral sclerosis	2.13e-06	0.000587	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.13e-06	0.000586	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—C3—amyotrophic lateral sclerosis	2.12e-06	0.000583	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	2.08e-06	0.000573	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	2.03e-06	0.000558	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	2.01e-06	0.000553	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PLB1—amyotrophic lateral sclerosis	1.97e-06	0.000543	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.97e-06	0.000543	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.95e-06	0.000537	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.94e-06	0.000535	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CHAT—amyotrophic lateral sclerosis	1.92e-06	0.000529	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	1.87e-06	0.000516	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.85e-06	0.000509	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—C3—amyotrophic lateral sclerosis	1.84e-06	0.000507	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GSR—amyotrophic lateral sclerosis	1.82e-06	0.000502	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—IGF1—amyotrophic lateral sclerosis	1.77e-06	0.000488	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	1.77e-06	0.000486	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.76e-06	0.000485	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.75e-06	0.000482	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CHAT—amyotrophic lateral sclerosis	1.75e-06	0.000482	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.71e-06	0.000471	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	1.67e-06	0.00046	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.66e-06	0.000457	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.6e-06	0.000442	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.6e-06	0.00044	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.53e-06	0.000421	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	1.52e-06	0.000419	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.51e-06	0.000415	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CHAT—amyotrophic lateral sclerosis	1.5e-06	0.000412	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.42e-06	0.00039	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	1.41e-06	0.000387	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.37e-06	0.000376	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.36e-06	0.000376	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.34e-06	0.000368	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.33e-06	0.000367	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.31e-06	0.00036	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.25e-06	0.000345	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.25e-06	0.000345	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.23e-06	0.000339	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.23e-06	0.000338	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.2e-06	0.00033	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.17e-06	0.000321	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—VEGFA—amyotrophic lateral sclerosis	1.16e-06	0.000319	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	1.15e-06	0.000318	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.15e-06	0.000316	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.09e-06	0.000301	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.09e-06	0.000299	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.06e-06	0.000291	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—APOE—amyotrophic lateral sclerosis	1.03e-06	0.000284	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.03e-06	0.000284	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.01e-06	0.000279	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—APOE—amyotrophic lateral sclerosis	1.01e-06	0.000278	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.01e-06	0.000277	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	9.63e-07	0.000265	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.49e-07	0.000261	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	9.48e-07	0.000261	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.41e-07	0.000259	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	9.35e-07	0.000258	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	9.25e-07	0.000255	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—TP53—amyotrophic lateral sclerosis	8.74e-07	0.000241	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	8.72e-07	0.00024	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—APOE—amyotrophic lateral sclerosis	8.69e-07	0.000239	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	8.65e-07	0.000238	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	8.36e-07	0.00023	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	8.04e-07	0.000221	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—APOE—amyotrophic lateral sclerosis	7.8e-07	0.000215	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	7.61e-07	0.00021	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	7.41e-07	0.000204	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.39e-07	0.000203	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	7.18e-07	0.000198	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—APOE—amyotrophic lateral sclerosis	7.11e-07	0.000196	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.07e-07	0.000195	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	7e-07	0.000193	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PTGS2—amyotrophic lateral sclerosis	6.91e-07	0.00019	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	6.44e-07	0.000177	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	6.29e-07	0.000173	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.2e-07	0.000171	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	6.08e-07	0.000167	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—APOE—amyotrophic lateral sclerosis	6.08e-07	0.000167	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.95e-07	0.000164	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.7e-07	0.000157	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	5.46e-07	0.00015	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.35e-07	0.000147	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.22e-07	0.000144	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.92e-07	0.000135	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.87e-07	0.000134	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.75e-07	0.000131	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	4.69e-07	0.000129	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.16e-07	0.000115	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.13e-07	0.000114	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.21e-07	8.85e-05	CbGpPWpGaD
